Furthermore, they identified CISH-/- as a method to increase the vulnerability of tumours to a type of cancer immunotherapy referred to as checkpoint inhibition, using in vivo models; this later formed the basis of a clinical trial for treating certain gastrointestinal cancers using CISH-/- TIL (41). The gene discussed is CISH; the disease is neoplasm.